MMSupport.net unveils “Ask the Expert”, featuring Multiple Myeloma physician and scientist, James R. Berenson, M.D.
Ask the Expert is a free online web-forum where Myeloma and Bone Cancer specialist, Dr. James R. Berenson offers medical answers to questions surrounding quality of life and longevity issues for patients living with this rare form of cancer.
Los Angeles, CA – MMSupport.net and the Institute for Myeloma and Bone Cancer Research are proud to announce the creation of “Ask the Expert”, a free online web-forum featuring Multiple Myeloma expert, Dr. James R. Berenson.
MMSupport.net is the creation of myeloma-advocate, Beth Morgan. The website serves to foster community in the form of an online forum where patients and caregivers could learn more about Multiple Myeloma, a plasma cell cancer that resides in the bone marrow. Thousands of people visit MMSupport.net every day. Many visitors are Myeloma and Bone Cancer patients, caregivers and other medical professionals who actively participate in online discussions about treatment options and personal experiences. “Ask the Expert” is the latest addition to the MMSupport.net website and is available at no charge by registering on the site. Visit www.mmsupport.net for more information.
James R. Berenson, MD has 25 years experience in treating Multiple Myeloma and Bone Cancer patients. Dr. Berenson is CEO and Medical Director for The Institute for Myeloma and Bone Cancer Research and CEO and President of Oncotherapeutics, an oncology-specific clinical trials management service. Dr. Berenson is an active clinician who treats patients daily in his Los Angeles offices and acts as a specialist consult to patient’s primary oncologist or primary care physician throughout the world. For more information, visit www.berensononcology.com
The Institute for Myeloma and Bone Cancer Research, based in Los Angeles, California, is an independent cancer research institute with a primary focus on hematologic cancers. Established in 2004, the IMBCR is a 501 c (3) non-profit organization. Over the last four years, the IMBCR has created novel breakthrough therapies that have substantially increased the longevity and quality of life of myeloma patients. The latest initiative at the institute is “The Cure Myeloma Project”, a multi-year research project that targets myeloma cells while keeping the non-cancerous cells intact. For more information or to make a donation, visit www.imbcr.org
Beth Morgan, MMsupport.net email@example.com or,
Cheryl A. Cross, MPH, Institute for Myeloma and Bone Cancer Research firstname.lastname@example.org 866-900-1035